Literature DB >> 24156273

Endothelial Krüppel-like factor 4 modulates pulmonary arterial hypertension.

Mohammad A Shatat1, Hongmei Tian, Rongli Zhang, Gaurav Tandon, Andrew Hale, Jason S Fritz, Guangjin Zhou, José Martínez-González, Cristina Rodríguez, Hunter C Champion, Mukesh K Jain, Anne Hamik.   

Abstract

Krüppel-like factor 4 (KLF4) is a transcription factor expressed in the vascular endothelium, where it promotes anti-inflammatory and anticoagulant states, and increases endothelial nitric oxide synthase expression. We examined the role of endothelial KLF4 in pulmonary arterial (PA) hypertension (PAH). Mice with endothelial KLF4 knockdown were exposed to hypoxia for 3 weeks, followed by measurement of right ventricular and PA pressures, pulmonary vascular muscularization, and right ventricular hypertrophy. The effect of KLF4 on target gene expression was assessed in lungs from these mice, verified in vitro by small interfering RNA (siRNA) knockdown of KLF4, and further studied at the promoter level with cotransfection experiments. KLF4 expression was measured in lung tissue from patients with PAH and normal control subjects. We found that, after hypoxia, right ventricular and PA pressures were significantly higher in KLF4 knockdown animals than controls. Knockdown animals also had more severe pulmonary vascular muscularization and right ventricular hypertrophy. KLF4 knockdown resulted in increased pulmonary expression of endothelin-1 and decreased expression of endothelial nitric oxide synthase, endothelin receptor subtype B, and prostacyclin synthase. Concordant findings were observed in vitro, both with siRNA knockdown of KLF4 and promoter activity assays. Finally, KLF4 expression was reduced in lungs from patients with PAH. In conclusion, endothelial KLF4 regulates the transcription of genes involved in key pathways implicated in PAH, and its loss exacerbates pulmonary hypertension in response to chronic hypoxia in mice. These results introduce a novel transcriptional modulator of PAH, with the potential of becoming a new therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24156273      PMCID: PMC4068930          DOI: 10.1165/rcmb.2013-0135OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  35 in total

Review 1.  Pulmonary arterial hypertension.

Authors:  Harrison W Farber; Joseph Loscalzo
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

2.  Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells.

Authors:  P M Hassoun; V Thappa; M J Landman; B L Fanburg
Journal:  Proc Soc Exp Biol Med       Date:  1992-02

3.  Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor.

Authors:  T Sakurai; M Yanagisawa; Y Takuwa; H Miyazaki; S Kimura; K Goto; T Masaki
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

Review 4.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

5.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

6.  Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis.

Authors:  M W Geraci; M Moore; T Gesell; M E Yeager; L Alger; H Golpon; B Gao; J E Loyd; R M Tuder; N F Voelkel
Journal:  Circ Res       Date:  2001-03-30       Impact factor: 17.367

7.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

Review 8.  Cellular and molecular pathobiology of pulmonary arterial hypertension.

Authors:  Marc Humbert; Nicholas W Morrell; Stephen L Archer; Kurt R Stenmark; Margaret R MacLean; Irene M Lang; Brian W Christman; E Kenneth Weir; Oliver Eickelberg; Norbert F Voelkel; Marlene Rabinovitch
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

9.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

Review 10.  Inflammation in pulmonary arterial hypertension.

Authors:  P Dorfmüller; F Perros; K Balabanian; M Humbert
Journal:  Eur Respir J       Date:  2003-08       Impact factor: 16.671

View more
  26 in total

1.  Therapeutic Engagement of the Histone Deacetylase IIA-Myocyte Enhancer Factor 2 Axis Improves Experimental Pulmonary Hypertension.

Authors:  Avraham Sofer; Seyoung Lee; Irinna Papangeli; Takaomi Adachi; Cheol Hwangbo; Suzy Comhair; Paul DaSilva-Jardine; Jongmin Kim; John J Schwarz; Serpil C Erzurum; Hyung J Chun
Journal:  Am J Respir Crit Care Med       Date:  2018-11-15       Impact factor: 21.405

Review 2.  Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).

Authors:  Soni S Pullamsetti; Frédéric Perros; Prakash Chelladurai; Jason Yuan; Kurt Stenmark
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 3.  Krüppel-like factors and vascular wall homeostasis.

Authors:  Yanbo Fan; Haocheng Lu; Wenying Liang; Wenting Hu; Jifeng Zhang; Y Eugene Chen
Journal:  J Mol Cell Biol       Date:  2017-10-01       Impact factor: 6.216

4.  HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4.

Authors:  Andrew T Hale; Chris T Longenecker; Ying Jiang; Sara M Debanne; Danielle E Labatto; Norma Storer; Anne Hamik; Grace A McComsey
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

Review 5.  'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.

Authors:  Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf
Journal:  Genes (Basel)       Date:  2020-11-26       Impact factor: 4.096

6.  Endothelial Tenascin-X Is Going With the Flow.

Authors:  Soon Yew Tang; Garret A FitzGerald
Journal:  Circ Res       Date:  2022-05-26       Impact factor: 23.213

7.  Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension.

Authors:  Zeyu Zhang; Chunlei Liu; Yongyi Bai; Xin Li; Xiaojian Gao; Chen Li; Ge Guo; Si Chen; Mingzhuang Sun; Kang Liu; Yang Li; Kunlun He
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

8.  Endothelial Kruppel-like factor 4 regulates angiogenesis and the Notch signaling pathway.

Authors:  Andrew T Hale; Hongmei Tian; Ejike Anih; Fernando O Recio; Mohammad A Shatat; Trent Johnson; Xudong Liao; Diana L Ramirez-Bergeron; Aaron Proweller; Masakazu Ishikawa; Anne Hamik
Journal:  J Biol Chem       Date:  2014-03-05       Impact factor: 5.157

9.  Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension.

Authors:  Abdul Q Sheikh; Ashish Misra; Ivan O Rosas; Ralf H Adams; Daniel M Greif
Journal:  Sci Transl Med       Date:  2015-10-07       Impact factor: 17.956

10.  Evolutionary Protection of Krüppel-Like Factors 2 and 4 in the Development of the Mature Hemovascular System.

Authors:  David R Sweet; Cherry Lam; Mukesh K Jain
Journal:  Front Cardiovasc Med       Date:  2021-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.